Mora-Montes de Oca O, Zumalacárregui-de Cárdenas L, Regalado-Fonseca I, Hernández-de la Rosa L

Language: Spanish
References: 21
Page: 60-68
PDF size: 438.07 Kb.

ABSTRACT

The use of monoclonal antibodies in the fight against cancer is becoming more and more the selected therapy. The introduction of monoclonal antibodies highly demanded in international markets, with high quality requirements needs the production of monoclonal antibodies on a large scale. The increase of dimers in the final product affects its quality, therefore, the efficiency and effectiveness of the process. The objective of this work was to obtain a mathematical model to relate the percentage of dimers with the most influential operating variables. A multiple linear regression model was obtained using Statgraphics Centurion XVII version 17.2.00 software. The model was validated with new production data with a mean error of validation below 20%. The significant variables were: supernatant IgG mass; IgG mass in the effluent from Protein A capture column; pH of the effluent from Protein A capture column; pH of the adjusted product and conductivity of the effluent from anionic exchange membrane. A working interval for each of the influential variables were established, in order to reduce dimers below 3%.

REFERENCES

1. Ministerio de Salud Pública Cuba. Anuario estadistico de Salud,2009.La Habana: Ministerio de Salud Publica; 2020.]

2. Pérez-Ruiz L, Rodríguez-Mendoza M, Soto-Molina H, Galán-Alvarez Y, Viada-Gonzalez CE, Collazo-Herrera MM. Nimotuzumab (CIMAher(r)) en pacientes cubanos con cáncer de cabeza y cuello estadíos III/IV: Análisis de impacto presupuestario.VacciMonitor. 2020; 29(1):14-21.Disponible en: http://scielo.sld.cu/pdf/vac/v29n1/1025-0298-vac-29-01-14.pdf]

3. Viada C, Vega A, Robaina M, Frías A, Álvarez M, Santiesteban Y, et al. Evaluación de Nimotuzumab para el tratamiento de cáncer de cabeza y cuello:Meta análisis de ensayos controlados. Revista Bionatura. 2020;5:1056-62. Disponible en:http://revistabionatura.com/files/2020.05.01.8.pdf]

4. Saborido L, Soriano J, Álvarez S, González Z, Riquelme I. Evaluación del efecto antitumoral del nimotuzumab combinado con radioquimioterapia en tumores de esófago. Rev Cubana Farm. 2015;49(2):254-70. Disponible en: http://scielo.sld.cu/pdf/far/v49n2/far07215.pdf]

5. Mora O. Impacto de un medio de cultivo alternativo en el proceso de purificación del Nimotuzumab. ENT#091;Tesis para optar por el título de Ingeniero QuímicoENT#093;. La Habana: Universidad Tecnológica de La Habana "José Antonio Echeverría"; 2015.]

6. Courtois F, Agrawal N, Lauer T, Trut B. Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab. MAbs. 2016;8(1):99-112. doi: https://10.1080/19420862.2015.1112477]

7. González, M. Is your biologic at risk for protein aggregation? Part 1. New York: Pfizer CentreOne;2018 Disponible en: https://www.pharmaceuticalonline.com/doc/is-your-biologic-at-risk-for-protein-aggregation-part-0001.]

8. Liu B, Guo H, Xu J, Qin T, Xu L, Zhang J, et al. Acid-induced aggregation propensity of nivolumab is dependent on the Fc. Mabs. 2016;8(6):1107-17. doi: https://10.1080/19420862.2016.1197443]

9. van der Kant R, Karow-Zwick A, Van Durme J, Blech M, Gallardo R, Seeliger D et al. Prediction and Reduction of the Aggregation of Monoclonal Antibodies. J Mol Biol.2017;429:1244-61. doi: https://10.1016/j.jmb.2017.03.014]

10. Singla A, Bansal R, Joshi V, Rathore AS. Aggregation Kinetics for IgG1-Based Monoclonal Antibody Therapeutics. AAPS J 2016;18(3):689-702. doi: https://10.1208/s12248-016-9887-0]

11. Joshi V, Yadav N, Rathore AS. Aggregation of Monoclonal Antibody Products: Formation and Removal. BioPharm Int. 2013;26(3):5. Disponible en: https://www.biopharminternational.com/view/aggregation-monoclonal-antibody-products-formation-and-removal]

12. Piña W, Feliu V, Rivas R. Direct Continuous-Time System Identification of the Purification Process of the Nimotuzumab, a Humanized Monoclonal Antibody. IEEE Latin American Transactions. 2018;16(1):31-7. doi: https://10.1109/TLA.2018.8291451]

13. CMC Biotech Working Group. A-MAb: case study on bioprocess development. Emerville: CASSS; 2009.]

14. Regalado I, Mora O, Zumalacárregui L. Aplicación del análisis de componentes principales en la formación de dímeros durante la purificación de un anticuerpo monoclonal. VacciMonitor. 2020;29(3):109-17. Disponible en: http://scielo.sld.cu/pdf/vac/v29n3/1025-0298-vac-29-03-109.pdf.]

15. Jolliffe IT. Principal Component Analysis. Second edition. New York:SpringerVerlag;2002.]

16. Zhang X., Lester RL, Dickson RC. Pil1p and Lsp1p Negatively Regulate the 3-Phosphoinositide-dependent Protein Kinase-like Kinase Pkh1p and Downstream Signaling Pathways Pkc1p and Ypk1p. J Biol Chem. 2004;279(21):22030-8.]

17. Vázquez M, Lang D. Aggregates in monoclonal antibody manufacturing processes. Biotechnology and Bioengineering. 2011;108(7):1494-1508.]

18. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010; 27(4):544-75.]

19. Krishnamurthy R, Manning M. The Stability Factor: Importance in Formulation Development. Curr Pharm Biotechnol. 2002;3:361-71.]

20. Fesinmeyer RM, Hogan S, Saluja A, Brych S R, Kras E,. Narhi LO et al. Effect of Ions on Agitation- and Temperature-Induced Aggregation Reactions of Antibodies. Pharm Res. 2009;26(4):903-13.]

21. Mazzer A, Perraud X, Halley J, O´Hara J, Bracewell D. Protein A chromatography increases monoclonal antibody aggregation rate during subsequent low pH virus inactivation hold. J Chromatogr A. 2015;1415 (10):83-90. doi: https://10.1016/j.chroma.2015.08.068.]